Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy

European Journal of Heart Failure

Volumn 13, Issue 5, 2011, Pages 543-550

  Smit, Marcelle D ^a   Maass, Alexander H ^a   Hillege, Hans L ^a   Wiesfeld, Ans C P ^a   Van Veldhuisen, Dirk J ^a   Van Gelder, Isabelle C ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Atrial fibrillation; Atrial natriuretic peptide; Cardiac resynchronization therapy; Mortality; N terminal pro B type Natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; NATRIURETIC FACTOR;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

AGED; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 79955397670     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr006     Document Type: Article

References (37)

1. Neuberger HR, Mewis C, van Veldhuisen DJ, Schotten U, Van Gelder IC, Allessie MA, Bohm M. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007;28:2568-2577. (Pubitemid 350071511)
2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
3. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549. (Pubitemid 40517094)
4. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Document Reviewers, Tendera M, Anker SD, Blanc JJ, Gasparini M, Hoes AW, Israel CW, Kalarus Z, Merkely B, Swedberg K, Camm AJ. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-1153.
5. Leclercq C, Padeletti L, Cihak R, Ritter P, Milasinovic G, Gras D, Paul V Van Gelder IC, Stellbrink C, Rieger G, Corbucci G, Albers B, Daubert JC, CHAMP Study Investigators. Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics. Europace 2010;12:71-77.
6. Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF, Mandava A, Mittal S, Steinberg JS. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol 2009;53:1050-1055.
7. Leclercq C, Victor F, Alonso C, Pavin D, Revault d'Allones G, Bansard JY, Mabo P, Daubert C. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation. Am J Cardiol 2000;85:1154-1156. (Pubitemid 30214269)
8. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, McKenna W, Fitzgerald M, Deharo JC, Alonso C, Walker S, Braunschweig F, Bailleul C, Daubert JC. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-118. (Pubitemid 34701385)
9. Molhoek SG, Bax JJ, Bleeker GB, Boersma E, Van Erven L, Steendijk P, Van der Wall EE, Schalij MJ. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol 2004;94:1506-1509. (Pubitemid 40268451)
10. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B, Curnis A, Vogt J, Klersy C. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008;29:1644-1652. (Pubitemid 351957539)
11. Buck S, Rienstra M, Maass AH, Nieuwland W, Van Veldhuisen DJ, Van Gelder IC. Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time. Europace 2008;10:558-565. (Pubitemid 351775289)
12. Tolosana JM, Hernandez Madrid A, Brugada J, Sitges M, Garcia Bolao I, Fernandez Lozano I, Martinez Ferrer J, Quesada A, Macias A, Marin W, Escudier JM, Gomez AA, Gimenez Alcala M, Tamborero D, Berruezo A, Mont L, SPARE Investigators. Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] study). Am J Cardiol 2008;102:444-449.
13. Dickstein K, Aarsland T, Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Card Fail 1997;3: 83-89. (Pubitemid 127675011)
14. Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P, COMET Investigators. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9:795-801. (Pubitemid 47225165)
15. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 2006;8:482-487. (Pubitemid 43985484)
16. Maass AH, Buck S, Nieuwland W, Brugemann J, Van Veldhuisen DJ Van Gelder IC. Importance of heart rate during exercise for response to cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2009;20:773-780.
17. De Vos CB, Weijs B, Crijns HJ, Cheriex EC, Palmans A, Habets J, Prins MH, Pisters R, Nieuwlaat R, Tieleman RG. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2009;95:835-840.
18. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Document Reviewers, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360-1420.
19. Hügl B, Bruns HJ, Unterberg-Buchwald C, Grosse A, Stegemann B, Lauer B, Geller JC, Gasparini M. Atrial fibrillation burden during the post-implant period after CRT using device-based diagnostics. J Cardiovasc Electrophysiol 2006;17: 813-817. (Pubitemid 44079738)
20. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J III, St John Sutton M, De Sutter J, Murillo J. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008;117:2608-2616.
21. Fornwalt BK, SpragueWW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA, Leon AR, Oshinski JN. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010;121:1985-1991.
22. Molhoek SG, Bax JJ, Van Erven L, Bootsma M, Steendijk P, Lentjes E, Boersma E, Van der Laarse A, Van derWall EE, Schalij MJ. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004;90:97-98. (Pubitemid 38064558)
23. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M, Francolini G, Diemberger I, Bacchi L, Rapezzi C, Ferrari R, Branzi A. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 2006; 27:1776-1786. (Pubitemid 43880376)
24. Van den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Depletion of atrial natriuretic peptide during longstanding atrial fibrillation. Europace 2004;6:433-437.
25. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P, Pini D, Ceriotti C, Gronda E, Klersy C, Fratini S, Klein HH. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006;48:734-743. (Pubitemid 44175735)
26. Ferreira AM, Adragao P, Cavaco DM, Candeias R, Morgado FB, Santos KR, Santos E, Silva JA. Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace 2008;10:809-815. (Pubitemid 351882072)
27. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-341.
28. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, Verheugt FW, Lie KI. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585-2592. (Pubitemid 26404796)
29. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, Bosker HA, Lok DJ, Van Veldhuisen DJ, Van Gelder IC. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-1792.
30. Smit MD, Van Dessel PF, Rienstra M, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, Van Veldhuisen DJ, Van Gelder IC. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. Europace 2006;8:566-572. (Pubitemid 44295749)
31. Buck S, Maass AH, Van Gelder IC. How to prevent ICD shocks: part II. Europace 2008;10:1126-1129.
32. Borleffs CJ, Van Rees JB, VanWelsenes GH, Van der Velde ET, Van Erven L, Bax JJ, Schalij MJ. Prognostic importance of atrial fibrillation in implantable cardioverterdefibrillator patients. J Am Coll Cardiol 2010;55:879-885.
33. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM, Widdershoven JW, Baur LH, Levy S, Crijns HJ. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2008;29:1181-1189. (Pubitemid 351844895)
34. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25. (Pubitemid 44305270)
35. Delnoy PP, Ottervanger JP, Luttikhuis HO, Elvan A, Misier AR, Beukema WP, Van Hemel NM. Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. Am J Cardiol 2007;99:1252-1257. (Pubitemid 46659863)
36. Dong K, Shen WK, Powell BD, Dong YX, Rea RF, Friedman PA, Hodge DO, Wiste HJ,Webster T, Hayes DL, Cha YM. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm 2010;7:1240-1245.
37. Rienstra M, Van Gelder IC, Hagens VE, Veeger NJ, Van Veldhuisen DJ, Crijns HJ. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. Eur Heart J 2006;27:357-364. (Pubitemid 43100033)